Abstract: A method includes forming a first conductive feature over a semiconductor substrate, forming an ILD layer over the first conductive feature, patterning the ILD layer to form a trench, and forming a conductive layer over the patterned ILD layer to fill the trench. The method further includes polishing the conductive layer to form a via contact configured to interconnect the first conductive feature with a second conductive feature, where polishing the conductive layer exposes a top surface of the ILD layer, polishing the exposed top surface of the ILD layer, such that a top portion of the via contact protrudes from the exposed top surface of the ILD layer, and forming the second conductive feature over the via contact, such that the top portion of the via contact extends into the second conductive feature.

Abstract: A display apparatus includes a substrate, a pixel structure, a back side signal line, and a conductive shielding layer. The substrate has a first surface and a second surface opposite to each other. The pixel structure is disposed on the first surface of the substrate. The back side signal line is disposed on the second surface of the substrate and is electrically connected to the pixel structure. The conductive shielding layer is disposed between the pixel structure and the first surface of the substrate, and the conductive shielding layer has a DC level. Moreover, other display apparatuses are also provided.

Abstract: An optoelectronic package includes a first photonic component, an optical connection element and an optical component. The optical connection element is disposed at least partially over the first photonic component. The optical component is disposed at least partially over the first photonic component. The optical connection element and the optical component are spaced apart from each other.

Abstract: Some implementations described herein provide a semiconductor structure. The semiconductor structure includes a first terminal coupled to a substrate of the semiconductor structure, with the first terminal including a first portion of a tunneling layer formed on the substrate, and a first gate formed on the first portion of the tunneling layer. The semiconductor structure includes a second terminal coupled to the substrate and adjacent to the first terminal, with the second terminal including a second portion of the tunneling layer formed on the substrate, a second gate formed on the second portion of the tunneling layer, and a dielectric structure formed on a top surface and side surfaces of the second gate. The semiconductor structure includes a third terminal coupled to an insulating structure and adjacent to the second terminal, with the third terminal including, a third gate formed on the insulating structure.

Abstract: An optoelectronic package structure is provided. The optoelectronic package includes a carrier, an electronic component, a photonic component and a first power supply path in the carrier. The carrier includes a first region and the electronic component is disposed over the first region of the carrier. A first power supply path is electrically connects the electronic component.

Abstract: An electronic device package includes a substrate, a first semiconductor die, a second semiconductor die and an encapsulant. The substrate includes a first surface, and a second surface opposite to the first surface. The substrate defines a cavity recessed from the first surface. The first semiconductor die is disposed in the cavity. The second semiconductor die is disposed over and electrically connected to the first semiconductor die. The encapsulant is disposed in the cavity of the substrate. The encapsulant encapsulates a first sidewall of the first semiconductor die, and exposes a second sidewall of the first semiconductor die.

Abstract: A transient voltage suppression device includes at least one N-type lightly-doped structure, a first P-type well, a second P-type well, a first N-type heavily-doped area, and a second N-type heavily-doped area. The first P-type well and the second P-type well are formed in the N-type lightly-doped structure. The first N-type heavily-doped area and the second N-type heavily-doped area are respectively formed in the first P-type well and the second P-type well. The doping concentration of the first P-type well is higher than that of the second P-type well. The first P-type well and the second P-type well can be replaced with P-type lightly-doped wells respectively having P-type heavily-doped areas under the N-type heavily-doped areas.

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.

Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.

Abstract: A measuring device of Chinese medicine granules includes a dispensing tray, a fixed discharging cover, a discharging driving cover, and a discharging anti-blocking structure mounted coaxially. The dispensing tray, the fixed discharging cover, and the discharging driving cover are provided with storage holes, measuring holes, and discharging holes, respectively. The discharging anti-blocking structure includes a bottom case, a briquetting holder, an anti-blocking briquette, a spring, and a cover. The bottom case is fixed on the dispensing tray and offsets from the storage hole. The bottom case is provided with dispensing holes therein positioned corresponding to the discharging holes. Each of the dispensing holes is provided with one anti-blocking briquette therein. The briquetting holder is connected to the anti-blocking briquette and is disposed in the bottom case. The spring is sleeved on the briquetting holder and is in contact with the cover.

Abstract: A method for screening host cells expressing a target protein is provided. The method includes the following steps: providing an expression vector, the expression vector including a promoter, a gene encoding a target protein and an FTH1 gene; transfecting the host cells with the expression vector; culturing the host cells in a medium; and adding iron ions to the medium, and screening the surviving host cells to obtain the host cells expressing the target protein. An expression vector and a method for establishing a cell line stably expressing an exogenous recombinant gene are also provided.

Abstract: The present disclosure provides a measuring device of Chinese medicine granules, which includes a dispensing tray, a fixed discharging cover, a discharging driving cover, and a discharging anti-blocking structure mounted coaxially. The dispensing tray, the fixed discharging cover, and the discharging driving cover are provided with storage holes, measuring holes, and discharging holes, respectively. The discharging anti-blocking structure includes a bottom case, a briquetting holder, an anti-blocking briquette, a spring, and a cover. The bottom case is fixed on the dispensing tray and offsets from the storage hole. The bottom case is provided with dispensing holes therein positioned corresponding to the discharging holes. Each of the dispensing holes is provided with one anti-blocking briquette therein. The briquetting holder is connected to the anti-blocking briquette and is disposed in the bottom case. The spring is sleeved on the briquetting holder and is in contact with the cover.

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.

Abstract: A load-bearing bone fixation composite includes a polymer matrix, a plurality of polymer fibers aligned along a common axis and disposed in the polymer matrix, wherein the polymer matrix binds the surface of the polymer fibers, and a plurality of high aspect ratio nanorods coating at least a portion of each of the polymer fibers, wherein the long axis of at least a portion of the nanorods is aligned with the common axis, and wherein the high aspect nanorods have an aspect ratio of 10 or greater. Further included is a bone fixation device including the foregoing composite. A method of bone fixation comprises affixing the foregoing composite to a site of a load-bearing bone fracture, or maxillofacial bone fracture. Also included are methods of making the composites.

Abstract: The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.

Abstract: A bone-repair composite includes a core and a sheath. The core is a first primary unit including a combination of a first set of yarns coated with a calcium phosphate mineral layer. The first set of yarns being made from a first group of one or more polymers. The sheath is a second primary unit a combination of a second set of yarns or one or more polymer coatings. The second set of yarns being made from a second group of one or more polymers, wherein the composite is made by covering the core with the sheath, and the composite is compression molded to allow the sheath to bond to the core. The bone-repair composite has a bending modulus comparable to that of a mammalian bone, such that the ratio of the core to the sheath is provided to maximize the mechanical strength of the bone-repair composite to mimic the mammalian bone.

Abstract: An in vitro method for screening a testing compound to evaluate its potential as a liver drug of the disclosure is provided. The method includes applying the testing compound to cells of an isolated human liver tumor cell line, named as ITRI-H28, measuring a cell viability of the cells and determining the effect of the testing compound on the cells by calculating a half maximal inhibitory concentration (IC50) of the testing compound.